{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:23:27Z","timestamp":1758479007008},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.thromres.2005.10.001","type":"journal-article","created":{"date-parts":[[2005,11,19]],"date-time":"2005-11-19T12:15:24Z","timestamp":1132402524000},"page":"529-534","source":"Crossref","is-referenced-by-count":16,"title":["Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations"],"prefix":"10.1016","volume":"118","author":[{"given":"H.A.","family":"Schwertner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"McGlasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Christopher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2005.10.001_bib1","first-page":"349","article-title":"Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2, ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2005.10.001_bib2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2005.10.001_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians' Health Study","volume":"321","author":"The Steering Committee of the Physicians' Health Study Research Group","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2005.10.001_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2005.10.001_bib5","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1161\/01.CIR.77.6.1324","article-title":"Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study","volume":"77","author":"Goldman","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2005.10.001_bib6","first-page":"1328","article-title":"ACC\/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)","volume":"28","author":"Ryan","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2005.10.001_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0002-9149(99)00324-0","article-title":"Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution","volume":"84","author":"Feldman","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2005.10.001_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.326.7380.82","article-title":"Platelet responsiveness to aspirin in patients with hyperlipidaemia","volume":"326","author":"Friend","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2005.10.001_bib9","first-page":"869","article-title":"Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function","volume":"103","author":"Cerletti","year":"1984","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.thromres.2005.10.001_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2141.1985.tb07467.x","article-title":"Cumulative antiplatelet effect of low-dose enteric coated aspirin","volume":"60","author":"Jakubowski","year":"1985","journal-title":"Br J Hematol"},{"key":"10.1016\/j.thromres.2005.10.001_bib11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/0002-9149(94)90317-4","article-title":"Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects","volume":"74","author":"Dabaghi","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2005.10.001_bib12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/clpt.1980.114","article-title":"Effects of aspirin on platelet aggregation as a function of dosage and time","volume":"27","author":"Paccioretti","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2005.10.001_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF00637504","article-title":"Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function","volume":"23","author":"Ross-Lee","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2005.10.001_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/0002-9149(92)91316-V","article-title":"Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men","volume":"69","author":"Jimenez","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2005.10.001_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/clpt.1983.47","article-title":"Aspirin kinetics and platelet aggregation in man","volume":"33","author":"Siebert","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2005.10.001_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1042\/cs0790037","article-title":"Effect of aspirin infusions on platelet function in humans","volume":"79","author":"Wilson","year":"1990","journal-title":"Clin. Sci."},{"key":"10.1016\/j.thromres.2005.10.001_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00558267","article-title":"Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function","volume":"35","author":"Bochner","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.thromres.2005.10.001_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/03007999709113322","article-title":"Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets","volume":"13","author":"Muir","year":"1997","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.thromres.2005.10.001_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/clpt.1981.158","article-title":"Salicylate metabolite kinetics after several salicylates","volume":"30","author":"Bochner","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2005.10.001_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF00548398","article-title":"Bioavailability of acetylsalicylic acid and salicylic acid from rapid- and slow-release formulations, and in combination with dipyridamole","volume":"22","author":"Brantmark","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2005.10.001_bib21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2165\/00003088-199121050-00006","article-title":"Bioequivalence of four 100 mg oral aspirin formulations in healthy volunteers","volume":"21","author":"Bochner","year":"1991","journal-title":"Clin Pharmacokinet"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384805003956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384805003956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,20]],"date-time":"2019-01-20T22:59:09Z","timestamp":1548025149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384805003956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0049384805003956"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2005.10.001","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}